Dr. Gadue studies cell fate decisions, focusing on endoderm and mesoderm specification using human embryonic stem (ES) cells and induced pluripotent stem (iPS).
Dr. De Leon-Crutchlow’s translational research program focuses on examining the pathophysiology of disorders of insulin regulation, identifying novel therapeutic targets, and developing new therapies for these conditions. The program approach includes patient-oriented research and bench research employing mouse models and primary islet cultures.
Fitness tools that monitor your daily use of energy, from counting steps to tracking sleep, have exploded in popularity. Researchers are developing better noninvasive, high-resolution methods to estimate how well the fundamental source of that energy - your mitochondria - are working, and they have recently had some important successes. Mitochondria are the tiny energy factories of our cells,
Christoph Seiler, PhD, received a Foerderer Fund for Excellence award at The Children’s Hospital of Philadelphia in 2015 to study this mechanism. German-born Dr. Seiler pointed out that “Foerderer,” in German, means supporter or sponsor. Its name is therefore apt, because the internal award program spurs research projects that need a bit of support to generate pilot data that can later help those projects stand out in the competitive awarding of external funds.
New research from The Children’s Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania details how a diabetes-related gene functions on a biological pathway that affects the release of insulin.
The term “stem cell,” stammzellen, was first used in 1868 by the German biologist Ernst Haeckel to describe the original, unicellular progenitor from which Dr. Haekel supposed all multicellular plant and animal life might have descended.
The Gadue Laboratory studies human pancreatic and hematopoietic development and associated diseases using human pluripotent stem cells, including embryonic stem cells and induced pluripotent stem cells.
The Congenital Hyperinsulinism Research Lab investigates genotype-phenotype correlations for genetic causes of hyperinsulinism in order to improve diagnosis and management.
This study is a 2 period, open label study that will evaluate the safety and efficacy of dasiglucagon in children between the ages of 3 months and 12 years.
Leading the way in understanding the delicate balance between the genetic, epigenetic, and environmental impacts on the development of endocrine disease.
